Acadia Pharmaceuticals Inc. (ACAD)

[Investors3]

" That's what baffles me on the share price implosion in which Acadia suffered just based on this one report. The severe risks associated with atypical antipsychotics has already been known for nearly two decades now. Consider this report from 2013, which was way before Nuplazid was ever approved by the FDA. Clinical evidence was already mounting and known for years that atypical antipsychotics cause the risk of death. That means the risks associated with Nuplazid shouldn't be an issues considering that the FDA and medical professionals have known about these problems for years."

Inoviorulez,

Thank you for that interesting report or presentation of factual opinion! I was still waiting to hear back from how they did at that conference, and was very surprised that all of a sudden serious negative accusations were being made about Acadia...it is always good to keep an open mind and listen to both sides, as it does affect the movement of a stock short term, but I am looking long term with this company and revenues are substantially up.

Thank you again.